Catheter Ablation for Nonsustained Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy
Catheter Ablation for Nonsustained Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy
Despite established implantable cardioverter-defibrillator (ICD) therapy and catheter
 ablation for sustained ventricular tachycardia (VT) in patients with ischemic heart disease
 (IHD) and reduced left ventricular ejection fraction (LVEF), the efficacy of catheter
 ablation in patients with nonsustained VT has been not yet clarified. The incidence of
 appropriate ICD therapy itself has been reported to be a worse prognostic factor in patients
 with reduced LVEF. Therefore theoretically the inhibition of these ventricular incidences can
 result in the prognostic improvement.To suppress ventricular arrhythmias aside from
 antiarrhythmic agents, catheter ablation has been developed prominently in this decade along
 with the technological improvement such as irrigated ablation catheters, three-dimensional
 mapping systems, multi-polar catheters, and image integration system with CT and MRI. The
 rationale of this trial is to study the efficacy of the eradication of arrhythmogenic
 substrate in ischemic cardiomyopathy with reduced LVEF and nonsustained VT on prevention of
 the occurrence of sustained VT/VF and ICD therapies.
Inclusion Criteria:

 -  left ventricular ejection fraction (TTE or MRI) ≤40%

 -  diagnosed ischemic heart disease

 -  nonsustained monomorphic VT with more than 5 beats in the record of the implantable
 cardioverter-defibrillator or in any means of electrocardiogram (ECG) including ECG
 monitor and holter monitoring

 -  ICD implantation with primary preventive indication

 Exclusion Criteria:

 -  ICD implantation within 2 months

 -  previously documented sustained VT/VF (over 30 seconds) or adequate ICD shock

 -  no written informed consent